Leveraging a Clinical Phase Ib Proof-of-Concept Study for the GPR40 Agonist MK-8666 in Patients With Type 2 Diabetes for Model-Informed Phase II Dose Selection.

Krug, A W; Vaddady, P; Railkar, R A; Musser, B J; Cote, J; Ederveen, Agh; Krefetz, D G; DeNoia, E; Free, A L; Morrow, L; Chakravarthy, M V; Kauh, E; Tatosian, D A; Kothare, P A

Krug, A W; Vaddady, P; Railkar, R A; Musser, B J; Cote, J; Ederveen, Agh; Krefetz, D G; DeNoia, E; Free, A L; Morrow, L; Chakravarthy, M V; Kauh, E; Tatosian, D A; Kothare, P A.

Affiliation

Krug AW; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Vaddady P; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Railkar RA; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Musser BJ; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Cote J; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Ederveen A; CBG-MEB, Utrecht, The Netherlands.
Krefetz DG; PRA Health Sciences, Marlton, New Jersey, USA.
DeNoia E; ICON Development Solutions, San Antonio, Texas, USA.
Free AL; Pinnacle Research Group, Anniston, Alabama, USA.
Morrow L; Profil Institute for Clinical Research, Chula Vista, California, USA.
Chakravarthy MV; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Kauh E; Eli Lilly & Co., Lilly Corporate Center, Indianapolis, IN 46285, USA.
Tatosian DA; Merck & Co., Inc., Kenilworth, New Jersesy, USA.
Kothare PA; Merck & Co., Inc., Kenilworth, New Jersesy, USA.

Clin Transl Sci ; 10(5): 404-411, 2017 Sep.

Article de En | MEDLINE | ID: mdl-28727908

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Récepteurs couplés aux protéines G / Diabète de type 2 Type d'étude: Clinical_trials / Prognostic_studies Limites: Adult / Aged / Humans / Middle aged Langue: En Journal: Clin Transl Sci Année: 2017 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google